• About Us
  • Board of Advisors
  • Contact

MALARIA.com

A Malaria Information and Community Portal

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
Home / Archives for PATH Malaria Vaccine Initiative (MVI)

RTS,S Malaria Vaccine Phase III Trial Results Show Promise, Though Diminished Effectiveness Over Time

April 27, 2015 By Malaria.com Leave a Comment

Final results from a large-scale Phase III trial of the RTS,S malaria vaccine candidate, including the impact of a booster dose, published today in The Lancet, show that the vaccine candidate helped protect children and infants from clinical malaria for at least three years after first vaccination. … [Read more...]

Filed Under: Malaria News Tagged With: GlaxoSmithKline, Malaria Vaccine, PATH Malaria Vaccine Initiative (MVI), RTS-S, RTSS Vaccine

Phase III Trial of RTS,S Malaria Candidate Vaccine Reduces Malaria by One Third

November 9, 2012 By Malaria.com Leave a Comment

Results from a pivotal, large-scale Phase III trial, published online today in the New England Journal of Medicine, show that the RTS,S malaria vaccine candidate can help protect African infants against malaria. When compared to immunization with a control vaccine, infants (aged 6-12 weeks at first vaccination) vaccinated with RTS,S had one-third fewer episodes of both clinical and severe malaria … [Read more...]

Filed Under: Malaria News Tagged With: Andrew Witty, Bill & Melinda Gates Foundation, Bill Gates, David Kaslow, GlaxoSmithKline, Malaria Vaccine, PATH Malaria Vaccine Initiative (MVI), RTSS Vaccine, Salim Abdulla

Study Finds Malaria Vaccine Candidate, RTS,S Significantly Reduces Malaria Risk in African Infants

October 18, 2011 By Malaria.com Leave a Comment

First results from a large-scale Phase III trial of RTS,S*, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & … [Read more...]

Filed Under: Malaria News Tagged With: Agenus Inc., Antigenics Inc., Bill & Melinda Gates Foundation, Francis Martinson, GlaxoSmithKline, Irving Hoffman, Malawi, PATH Malaria Vaccine Initiative (MVI), QS-21 Stimulon, RTSS Vaccine

RTS,S Malaria Vaccine

October 8, 2011 By Malaria Q&A 10 Comments

QUESTION: What information can you provide on this vaccine candidate? ANSWER: RTS,S is a vaccine candidate against Plasmodium falciparum malaria which works by encouraging the host's body to produce antibodies and T cells which diminish the malaria parasite's ability to survive and reproduce in the liver. Produced by GlaxoSmithKline, RTS,S is the first vaccine candidate against … [Read more...]

Filed Under: Malaria Q&A Tagged With: antibody productive, Bill & Melinda Gates Foundation, Gates Foundation, GlaxoSmithKline, Malaria Vaccine, Malaria Vaccine Initiative, PATH Malaria Vaccine Initiative (MVI), Phase III clinical trials, Plasmodium Falciparum, RTSS Vaccine

GSK and Johnson & Johnson Announce Malaria Vaccine Collaboration

April 6, 2011 By Malaria.com Leave a Comment

GlaxoSmithKline Biologicals (GSK Bio) and Crucell NV (Johnson & Johnson) have announced a collaboration to develop a vaccine approach aimed at boosting the efficacy of the world’s most clinically advanced malaria vaccine candidate, RTS,S. The PATH Malaria Vaccine Initiative (MVI) today congratulated the companies on the partnership. "We are excited by the potential of this new endeavor for … [Read more...]

Filed Under: Malaria News Tagged With: Ad26.CS, Ad35.CS, Ashley Birkett, Christian Loucq, Crucell, GlaxoSmithKline, GSK Bio, Johnson & Johnson, PATH Malaria Vaccine Initiative (MVI), Prime-Boost, RTS

Liquidia Technologies Gets $10M from Gates Foundation for Malaria Vaccine

March 4, 2011 By Malaria.com Leave a Comment

The Bill & Melinda Gates Foundation invested $10 million in Liquidia Technologies, a closely held biotechnology company developing vaccines, as part of a $400 million initiative to fund activities to help poorer countries. Liquidia is developing a seasonal flu vaccine and has an agreement with the PATH Malaria Vaccine Initiative to use its technology to work on new malaria vaccines, the … [Read more...]

Filed Under: Malaria News Tagged With: Gates Foundation, Liquidia Technologies, Malaria Vaccine, PATH Malaria Vaccine Initiative (MVI)

Professor Working on Malaria Vaccine that Will Inoculate Mosquitos When They Bite People

February 15, 2011 By Malaria.com Leave a Comment

The same menace that spreads malaria – the mosquito bite – could help wipe out the deadly disease, according to researchers working on a new vaccine at Tulane University. The PATH Malaria Vaccine Initiative(MVI), established in 1999 through a grant from the Bill & Melinda Gates Foundation, announced today a collaboration with Tulane University School of Public Health and Tropical Medicine … [Read more...]

Filed Under: Malaria News Tagged With: Gates Foundation, Gennova Biopharmaceuticals, Malaria Vaccine, PATH Malaria Vaccine Initiative (MVI), Pfs48/45, Tulane University

Stay Informed

WWARN Corner

About WWARN

The WorldWide Antimalarial Resistance Network (WWARN) generates innovative resources and reliable evidence to inform the malaria community on the factors affecting the efficacy of antimalarial medicines. Learn more…

  • Fighting Malaria Requires Protecting the Effectiveness of Antimalarial Medicines
  • Data Sharing at IDDO
  • Evidence to inform equitable dosing in very young and malnourished children

More WWARN Stories...

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
  • About Us
  • Board of Advisors
  • Contact

Copyright © 2023 Malaria.com · Log in